Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma

Hangzhou Qihan Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) approved its clinical trial application for the product QN-019a. It is the first IND approved in China for a gene-edited iPSC-derived cell therapy product.